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n¼274), andwere evaluated the outcomes.Outcomemeasures included in-
hospital complications (all-cause death, recurrent myocardial infarction,
stroke, major bleeding or access site complications that needed treatment)
and major adverse cardiovascular events (MACE: all-cause death, target
vessel revascularization, recurrent myocardial infarction, admission of
heart failure) at 3 years.
RESULTS Mean follow up period was 1211  750 days. In-hospital
complication rate was 7.8%in group 1, and 13.5% in group 2 at initial
hospitalization (P¼0.012). Kaplan-Meier survival curves showed that
freedom from MACE was 69.4% in group 1 and 61.9% in group 2 at 3
years (P¼0.077).
CONCLUSION Shorter door-to-balloon time was associated with less
in-hospital complications in patients with STEMI although it did not
reduce long-term MACE.
OTHER PHARMACOLOGIC AGENTS
(TCTAP A-093, TCTAP A-095 TO TCTAP A-096)
TCTAP A-093
Determinants of Self-Discontinuation of Secondary Prevention Medications
by Coronary Heart Disease Outpatients: Focus on the Role of Erectile
Dysfunction
Ali Yousif Nori,1 Bahar Ibrahim,1 Muhamad Ali S.K. Abdul Kader,2
Mohamed Azmi Hassali,1 Rahmat Awang1
1Universiti Sains Malaysia, Penang Island, Malaysia; 2Penang General
Hospital, Penang Island, Malaysia
BACKGROUND Despite the signiﬁcant beneﬁt of evidence-based
therapy in reducing the cardiovascular outcomes among ischemic
heart disease patients, many discontinue certain medications (Mx)
selectively.
METHODS This is a cross-sectional study included 187 non diabetic
patients with documented coronary heart disease. The interview took
place in the cardiology clinic of Penang General Hospital in Northern
Malaysia using a comprehensive medication review form to detect Mx
stopped by the patient, along with exploring the potential reasons.
Erectile dysfunction or ED (predictor of interest) was assessed using the
Malaysian version of the abridged International Index of the Erectile
Function (5-IIEF). In addition to sociodemographic factors, knowledge
about Mx names, errors in taking the prescribed regimen, experienced
adverse drug events (ADE), and use of anti-impotence Mx data were
obtained from the patient. Binary logistic regression was employed to
identify the relationships with Mx discontinuation (outcome).
RESULTS Forty-seven patients (25.1 %) had a history of discontinuing at
least oneMxwithout consulting their prescriber. Aspirinwas stoppedby 14
(7.6 %) patients, while 12 (6.4 %) and 15 (8 %) patients had a history of
discontinuing beta blocker sand statins, respectively. Two patients
declared induced-ED as reason for Mx discontinuation. Among many
others, inability to tolerate the ADE was the commonest (7.5 %). However,
ED was mentioned as ADE by 27 (14.4%) patients. After controlling of
sociodemographic factors; having non-CVD comorbidities [OR ¼ 0.313
(0.212 – 0.810)], wrongly taking the regimen [OR ¼ 3.19 (1.251 – 8.73)], and
lower erectile functioning [p¼ 0.034, OR¼ 0.880 (0.781 – 0.990)] were the
predictors signiﬁcantly associated with Mx discontinuation.
CONCLUSION Although many patients did not admit ED as cause for
Mx discontinuation, the majority had related it to the ADE. In addition
to the need for enhancing patients’ knowledge to accurately intake of
the prescribed doses, it is required to diagnose and consult about ED
related complaints in order to reduce the risk for personal discontin-
uation of vital secondary prevention therapy.
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BACKGROUND It is controversial that proton pump inhibitor (PPI) might
affect clopidogrel platelet response and can be associated with majoradverse cardiovascular events (MACEs) in patients (pts) undergoing
percutaneous coronary intervention (PCI). Particularly impact of PPI on pts
with triple antiplatelets (TAT) following PCI is largely unknown.
METHODS A total 3747 patients (pts) undergoing PCI from Oct 2004 to
Apr 2013 from prospective PCI registry were investigated. Exclusion
criteria were age of more than 80 years, cardiogenic shock, chronic
kidney disease (creatinine level2.0 or dialysis), in-hospital major
bleeding requiring transfusion (major hematoma or retroperitoneal
bleeding, gastro-intestinal bleeding), in-hospital death, and clinical
follow-up loss less than 1-year after PCI. The pts were classiﬁed
into dual antiplatelet therapy (DAT; aspirin+clopidogrel) and TAT
(DAT+cilostazol) according to discharge medication. Finally, 2209 pts
was enrolled in the DAT group and 697 pts in the TAT group. Major
clinical outcomes at one year were compared between the two groups.
RESULTS At baseline, age, gender, diabetes, hypertension, dyslipi-
demia, cerebrovascular accident, and current smoking were balanced
between PPI user and non-PPI user group in both DAT and TAT. Not
only in DAT group but also in TAT group, there was no signiﬁcant
differences in clinical outcomes including total death, cardiac death,
myocardial infarction, revascularization, all major adverse cardio-
vascular event (MACE), target lesion revascularization (TLR)-MACE,
target vessel revascularization (TVR)-MACE, and stent thrombosis
between PPI user and non-PPI user (Table).
CONCLUSION In our study, chronic PPI use was not associated with
adverse cardiovascular outcomes up to 1-year in Korean pts under-
going PCI regardless of DAT and TAT.
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BACKGROUND Myocardial necrosis triggers complement activation
and neutrophyl adhesion which is mediated by Intercellular Adhesion
Molecule (ICAM). Results from ARMYDTCTAP A-CAMS, showed that
Atorvastatin continuous treatment reduced ICAM value in patients
with stable angina pectoris. To date, there is no study yet which in-
vestigates the effect of acute Atorvastatin 80mg treatment in patients
with ST Segment Elevation Myocardial Infarction (STEMI) post
Primary Percutaneous Coronary Intervention (PPCI).
